BioCentury | Dec 31, 2020
Distillery Therapeutics

Transcription factor HSF1 as a colon cancer target

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Inhibiting HSF1, a mediator of the proteotoxic stress response, could treat colorectal cancer induced by chronic inflammation. In colon samples from four colitis-associated colon cancer patients, HSF1 protein levels...
BioCentury | Dec 4, 2020
Distillery Therapeutics

Scripps team discovers RNA-targeting small molecule for myotonic and corneal dystrophies

...DM1 and Fuchs endothelial corneal dystrophy, which are caused by CUG repeat expansions in DMPK and TCF4...
...muscleblind-like splicing regulator 1 (MBNL1); ATPase Ca++ transporting cardiac muscle fast twitch 1 (ATP2A1; SERCA1); transcription factor 4 (TCF4)EXPERIMENTAL...
BioCentury | Nov 14, 2020
Politics, Policy & Law

Candidates for next FDA commissioner

Four former FDA officials and an oncologist are on a list of candidates President-elect Joe Biden’s team is considering as FDA commissioner, individuals who are advising the transition team told BioCentury....
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 13, 2020
Product Development

Next-generation sickle cell readouts at ASH: Data Byte

The move toward sickle cell disease therapies that address the pathology’s root causes is reflected in promising early-stage readouts at ASH, which include both disease event rates and changes in red blood cell biology. The...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Small molecule ERG, FLI1 inhibitor identified for retinopathy of prematurity

DISEASE CATEGORY: Ophthalmic INDICATION: Retinopathy of prematurity A tool compound that inhibits multiple E26 transformation-specific transcription factors, including ERG and FLI1, could treat retinopathy associated with premature birth. In the oxygen-induced mouse model of retinopathy...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Antisense oligos against transcription factor DUX4 for a muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by aberrant expression of the transcription factor. Screening of seven locked nucleic acid (LNA) gapmer...
BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

Hesperos’ Human-on-a-Chip techIn an Advanced Therapeutics paper, a University of Central Florida team led by Hesperos Inc. co-founder and chief scientist James Hickman tested the efficacy of...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
Items per page:
1 - 10 of 1080